ES2606546T3 - Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar - Google Patents

Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar Download PDF

Info

Publication number
ES2606546T3
ES2606546T3 ES10721627.7T ES10721627T ES2606546T3 ES 2606546 T3 ES2606546 T3 ES 2606546T3 ES 10721627 T ES10721627 T ES 10721627T ES 2606546 T3 ES2606546 T3 ES 2606546T3
Authority
ES
Spain
Prior art keywords
weight
concentration
nicotine
group
flavanones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10721627.7T
Other languages
English (en)
Inventor
Dobromil KOSÍK
Milan Dittrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heglund AS
Original Assignee
Heglund AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CZ20090080A external-priority patent/CZ200980A3/cs
Application filed by Heglund AS filed Critical Heglund AS
Application granted granted Critical
Publication of ES2606546T3 publication Critical patent/ES2606546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El compuesto destinado a la aplicación bucal de nicotina al sistema circulatorio y a la distribución al sistema nervioso central, aplicable en forma coloidal o en forma de un dispositivo atomizador con el fin de dejar de fumar o de su sustitución en el caso de ser las condiciones para fumar desfavorables. De conformidad con la invención en referencia, el compuesto se destaca por el hecho, de que contiene una solución de nicotina en forma de base y/o de sus sales con un ácido orgánico en una concentración de 0,10 a 4,00% del peso, la concentración más apropiada es de 0,20 a 1,00% del peso. Además contiene materias que tienen efecto mucolítico del grupo de acetilcisteina en una concentración de 3,00 a 30,0% del peso y/o fitocomplejos que poseen efecto mucolítico, adquiridos mediante la extracción de las plantas seleccionadas del grupo Primula veris, Primula elatior, Hedera helix, Eucalyptus globulus nebo Liquiritia glabra en una concentración de0,50 a 15,00% del peso de fitocomplejo con un efecto antioxidante seleccionado del grupo de flavonas, flavonoles, flavanones flavanonoles, isoflavonas, neoflavonoides, antocianidinas, pro-antociadinas y de sus oligómeros y polímeros, adquiridos mediante la extracción de las plantas Camellia sinensis, Curcuma longa, Rosmarinus officinalis, Sylibium marianum, Vitis vinifera, Ginkgo biloba, Euterpe oleracea, Vaccinium myrtillus, Morinda citrifolia, Malpighia glabra, las cuales contienen además un retardador (amortiguador) que modifica la acidez a un rango de pH de 7,0 a 9,0.

Description

imagen1
imagen2
imagen3
imagen4
Ejemplos de realización:
Ejemplos 1, 2 y 3:
Componente:
Composición (% del peso)
Muestra nro.. 1
Muestra nro. 2 Muestra nro. 3
Nicotina
1,00 2,00 3,00
Ácido cítrico
0,95 1,55 2,10
Acetilcisteina
25,00 15,00 5,00
Ascorbil fosfato de sodio
3,00 5,00
Sorbato de potasio
0,10 0,10 0,10
Benzoato de sodio
0,10 0,10 0,10
Sucralosa
0,07 0,08 0,10
Glicerina
5,00 10,00 15,00
Grape seeda extrakt
1,50 0,75
Perfume
0,10 0,20 0,35
Aceite de ricina hidrogenado pegilado
0,12 0,12 0,12
Hidróxido de sodio
q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0
Agua
do 100,00g do 100,00g do 100,00g
Procedimiento de preparación: en el agua se disuelven componentes que se agregan individualmente de manera
5 paulatina. La solución se filtra según sea necesario y se vierte en recipientes de presión, dotados de una válvula dosificadora o en recipientes cerrados provistos de una válvula dosificadora, impulsada por una bomba de accionamiento manual.
Aprovechamiento industrial
De conformidad con la invención, el compuesto puede ser fabricado por la industria farmacéutica. El preparado 10 resulta apropiado para la absorción transmucosa de nicotina con el objetivo de dejar de fumar.
6

Claims (1)

  1. imagen1
ES10721627.7T 2009-02-11 2010-02-03 Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar Active ES2606546T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZ20090080 2009-02-11
CZ20090080A CZ200980A3 (cs) 2009-02-11 2009-02-11 Kompozice urcená k bukální absorpci nikotinu za úcelem odvykání kourení
CZ20090829 2009-12-09
CZ2009829 2009-12-09
PCT/CZ2010/000011 WO2010091649A2 (en) 2009-02-11 2010-02-03 A composition for buccal absorption of nicotine for the purpose of smoking cessation

Publications (1)

Publication Number Publication Date
ES2606546T3 true ES2606546T3 (es) 2017-03-24

Family

ID=69162740

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10721627.7T Active ES2606546T3 (es) 2009-02-11 2010-02-03 Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar

Country Status (14)

Country Link
US (2) US20110293535A1 (es)
EP (1) EP2395974B1 (es)
JP (1) JP2012517402A (es)
KR (1) KR20110114552A (es)
CN (1) CN102316850A (es)
AU (1) AU2010213244A1 (es)
CA (1) CA2751271A1 (es)
EA (1) EA201100896A1 (es)
ES (1) ES2606546T3 (es)
IL (1) IL212720A (es)
PT (1) PT2395974T (es)
SG (1) SG171870A1 (es)
WO (1) WO2010091649A2 (es)
ZA (1) ZA201103096B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US20140166028A1 (en) * 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit
US20140166027A1 (en) * 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
KR102705152B1 (ko) 2013-05-06 2024-09-09 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법
BR112015030543B8 (pt) * 2013-06-07 2022-05-24 Lea Shrivastava Preparação para aplicação tópica para o tratamento da pele e infecções da mucosa
KR102957402B1 (ko) 2013-12-05 2026-04-24 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
KR102721939B1 (ko) 2013-12-23 2024-10-25 쥴 랩스, 인크. 기화 디바이스 시스템 및 방법
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
KR20250012730A (ko) 2014-12-05 2025-01-24 쥴 랩스, 인크. 교정된 투여량 제어
CN104770864B (zh) * 2015-02-13 2016-08-24 华健 一种清热润喉的电子雾化液及其制备方法
WO2016133890A1 (en) * 2015-02-19 2016-08-25 Srq Patent Holdings, Llc Compositions for e-cigarettes
GB201516729D0 (en) * 2015-09-22 2015-11-04 The Technology Partnership Plc Liquid nicotine formulation
CA2914089C (en) 2015-12-03 2018-12-18 Euro-Pharm International Canada Inc. Nicotine-containing liquid formulations and uses thereof
MX388616B (es) 2016-02-11 2025-03-20 Juul Labs Inc Cartuchos de fijacion segura para dispositivos vaporizadores
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
WO2020151638A1 (zh) * 2019-01-25 2020-07-30 湖南中烟工业有限责任公司 一种水基电子烟烟液
KR102447537B1 (ko) 2019-10-10 2022-09-26 주식회사 케이티앤지 흡연 시스템
CN111000283A (zh) * 2019-12-13 2020-04-14 武汉红金叶新材料科技有限公司 一种用于气溶胶装置的电子烟油及其制备方法和应用
CA3164634A1 (en) 2019-12-19 2021-06-24 Juul Labs, Inc. Organic-based nicotine gel compositions
WO2021127101A1 (en) 2019-12-19 2021-06-24 Juul Labs, Inc. Metal oxide-based gel nicotine compositions
EP4076021A1 (en) 2019-12-20 2022-10-26 Juul Labs, Inc. Hydrated ionic clay and tobacco material compositions
SE546142C2 (en) * 2020-04-03 2024-06-11 Liw Innovation Ab New compositions for oral use
MX2023012528A (es) * 2021-04-23 2023-10-31 Thomas Meneghini Desinfectante y uso del mismo.
CN116649576B (zh) * 2023-06-14 2024-10-29 深圳市吉迩科技有限公司 一种含有抑菌抗氧化组合物的尼古丁口含制品及其制备方法
CN117099995A (zh) * 2023-09-05 2023-11-24 东莞市吉纯生物技术有限公司 一种抗氧化电子雾化液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63196524A (ja) * 1987-02-10 1988-08-15 Wakunaga Pharmaceut Co Ltd 経粘膜吸収型制ガン作用調節剤
IT1265312B1 (it) * 1993-12-21 1996-10-31 Indena Spa Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di
AU2190697A (en) * 1996-04-12 1997-11-07 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
AU2007216320B2 (en) * 2006-02-13 2010-10-28 Orient Pharma (Samoa) Co., Ltd. Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
WO2008069972A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Systems for effecting cessation of tobacco use
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0712308D0 (en) * 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition

Also Published As

Publication number Publication date
EA201100896A1 (ru) 2012-01-30
ZA201103096B (en) 2011-12-28
PT2395974T (pt) 2016-12-14
WO2010091649A3 (en) 2010-11-11
IL212720A0 (en) 2011-07-31
JP2012517402A (ja) 2012-08-02
AU2010213244A1 (en) 2010-08-19
WO2010091649A4 (en) 2010-12-29
KR20110114552A (ko) 2011-10-19
SG171870A1 (en) 2011-07-28
EP2395974B1 (en) 2016-09-07
EP2395974A2 (en) 2011-12-21
US20110293535A1 (en) 2011-12-01
WO2010091649A2 (en) 2010-08-19
US20200022905A1 (en) 2020-01-23
CN102316850A (zh) 2012-01-11
IL212720A (en) 2016-02-29
CA2751271A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
Khameneh et al. Phytochemicals: a promising weapon in the arsenal against antibiotic-resistant bacteria
WO2010091649A4 (en) A composition for buccal absorption of nicotine for the purpose of smoking cessation
JP6657296B2 (ja) 骨障害、軟骨障害又はその両方の管理又は改善用組成物及び方法
Zhu et al. Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model
AR113749A1 (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
AR078812A1 (es) Preparacion que comprende aminoacidos y plantas y su actividad en la detoxificacion del alcohol
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
US11964045B2 (en) Natural skin penetrating moisturizer formulations
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
ES2720954T3 (es) Formulaciones estabilizadas de estatina
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
CO6530152A1 (es) Composiciones de liberación controlada
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
ES2606141T3 (es) Composiciones para el tratamiento de úlceras periféricas de diversos orígenes
Ilijeva et al. Biological properties of some volatile phenylpropanoids
NO20084478L (no) Konjugerte lipidderivater
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
HRP20140215T1 (hr) Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika
Gupta et al. Comparison of antimicrobial activities of clove oil and its extract on some food borne microbes
EP2799082A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE
Kismet et al. Evaluation on scolicidal efficacy of propolis
ES2497667T3 (es) Sistema de emulsificación para usar en cosméticos
CN103585660A (zh) 一种新型空气清新剂
JP2016522255A5 (es)
EP2543374A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS WITH REBAMIPID AS AN ACTIVE SUBSTANCE